80 related articles for article (PubMed ID: 22155317)
1. Antisense oligonucleotide corrects splice abnormality in hereditary myopathy with lactic acidosis.
Sanaker PS; Toompuu M; McClorey G; Bindoff LA
Gene; 2012 Feb; 494(2):231-6. PubMed ID: 22155317
[TBL] [Abstract][Full Text] [Related]
2. Clinical manifestation and a new ISCU mutation in iron-sulphur cluster deficiency myopathy.
Kollberg G; Tulinius M; Melberg A; Darin N; Andersen O; Holmgren D; Oldfors A; Holme E
Brain; 2009 Aug; 132(Pt 8):2170-9. PubMed ID: 19567699
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotide therapeutics for iron-sulphur cluster deficiency myopathy.
Kollberg G; Holme E
Neuromuscul Disord; 2009 Dec; 19(12):833-6. PubMed ID: 19846308
[TBL] [Abstract][Full Text] [Related]
4. Myopathy with lactic acidosis is linked to chromosome 12q23.3-24.11 and caused by an intron mutation in the ISCU gene resulting in a splicing defect.
Olsson A; Lind L; Thornell LE; Holmberg M
Hum Mol Genet; 2008 Jun; 17(11):1666-72. PubMed ID: 18296749
[TBL] [Abstract][Full Text] [Related]
5. The defective splicing caused by the ISCU intron mutation in patients with myopathy with lactic acidosis is repressed by PTBP1 but can be derepressed by IGF2BP1.
Nordin A; Larsson E; Holmberg M
Hum Mutat; 2012 Mar; 33(3):467-70. PubMed ID: 22125086
[TBL] [Abstract][Full Text] [Related]
6. Tissue-specific splicing of ISCU results in a skeletal muscle phenotype in myopathy with lactic acidosis, while complete loss of ISCU results in early embryonic death in mice.
Nordin A; Larsson E; Thornell LE; Holmberg M
Hum Genet; 2011 Apr; 129(4):371-8. PubMed ID: 21165651
[TBL] [Abstract][Full Text] [Related]
7. The High Level of Aberrant Splicing of ISCU in Slow-Twitch Muscle May Involve the Splicing Factor SRSF3.
Rawcliffe DF; Österman L; Lindsten H; Holmberg M
PLoS One; 2016; 11(10):e0165453. PubMed ID: 27783661
[TBL] [Abstract][Full Text] [Related]
8. Use of antisense oligonucleotides to correct the splicing error in ISCU myopathy patient cell lines.
Holmes-Hampton GP; Crooks DR; Haller RG; Guo S; Freier SM; Monia BP; Rouault TA
Hum Mol Genet; 2016 Dec; 25(23):5178-5187. PubMed ID: 28007899
[TBL] [Abstract][Full Text] [Related]
9. Differences in RNA processing underlie the tissue specific phenotype of ISCU myopathy.
Sanaker PS; Toompuu M; Hogan VE; He L; Tzoulis C; Chrzanowska-Lightowlers ZM; Taylor RW; Bindoff LA
Biochim Biophys Acta; 2010 Jun; 1802(6):539-44. PubMed ID: 20206689
[TBL] [Abstract][Full Text] [Related]
10. PTBP1 acts as a dominant repressor of the aberrant tissue-specific splicing of ISCU in hereditary myopathy with lactic acidosis.
Rawcliffe DFR; Österman L; Nordin A; Holmberg M
Mol Genet Genomic Med; 2018 Nov; 6(6):887-897. PubMed ID: 30209894
[TBL] [Abstract][Full Text] [Related]
11. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
[TBL] [Abstract][Full Text] [Related]
12. Transient restoration of succinate dehydrogenase activity after rhabdomyolysis in iron-sulphur cluster deficiency myopathy.
Kollberg G; Melberg A; Holme E; Oldfors A
Neuromuscul Disord; 2011 Feb; 21(2):115-20. PubMed ID: 21196119
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide treatment for a pseudoexon-generating mutation in the NPC1 gene causing Niemann-Pick type C disease.
Rodríguez-Pascau L; Coll MJ; Vilageliu L; Grinberg D
Hum Mutat; 2009 Nov; 30(11):E993-E1001. PubMed ID: 19718781
[TBL] [Abstract][Full Text] [Related]
14. A novel de novo dominant mutation in
Legati A; Reyes A; Ceccatelli Berti C; Stehling O; Marchet S; Lamperti C; Ferrari A; Robinson AJ; Mühlenhoff U; Lill R; Zeviani M; Goffrini P; Ghezzi D
J Med Genet; 2017 Dec; 54(12):815-824. PubMed ID: 29079705
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
[TBL] [Abstract][Full Text] [Related]
16. Pseudoexon exclusion by antisense therapy in 6-pyruvoyl-tetrahydropterin synthase deficiency.
Brasil S; Viecelli HM; Meili D; Rassi A; Desviat LR; Pérez B; Ugarte M; Thöny B
Hum Mutat; 2011 Sep; 32(9):1019-27. PubMed ID: 21542064
[TBL] [Abstract][Full Text] [Related]
17. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
[TBL] [Abstract][Full Text] [Related]
18. Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance.
Mochel F; Knight MA; Tong WH; Hernandez D; Ayyad K; Taivassalo T; Andersen PM; Singleton A; Rouault TA; Fischbeck KH; Haller RG
Am J Hum Genet; 2008 Mar; 82(3):652-60. PubMed ID: 18304497
[TBL] [Abstract][Full Text] [Related]
19. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
Errington SJ; Mann CJ; Fletcher S; Wilton SD
J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
[TBL] [Abstract][Full Text] [Related]
20. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers.
Williams JH; Sirsi SR; Latta DR; Lutz GJ
Mol Ther; 2006 Jul; 14(1):88-96. PubMed ID: 16488666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
